T Cell Activation: How the Immune System Learns to Recognize a Threat

Antigen Presentation: Showing the Evidence

Before a T cell can respond to anything, it needs evidence that something is wrong, and that evidence has to be delivered in a very specific format. Dendritic cells, along with macrophages and B cells, act as antigen-presenting cells (APCs) that patrol tissues, engulf debris, pathogens, and dying cells, and break the proteins they collect into short peptide fragments. These fragments are loaded onto MHC molecules (major histocompatibility complex proteins) and carried to the cell surface like evidence bags held up for inspection. MHC class II molecules, found mainly on professional APCs, display peptides from material engulfed outside the cell, while MHC class I molecules, present on nearly all nucleated cells, display peptides made inside the cell itself, including viral proteins from an infected cell. This distinction matters enormously downstream. A dendritic cell that has sampled a bacterial infection travels to a nearby lymph node, where it presents its collection of MHC-peptide complexes to a constant stream of passing T cells, each of which carries a uniquely shaped receptor. Most of these encounters go nowhere. The system is built on trying enormous numbers of low-probability matches until, occasionally, one fits.

Signal 1: The TCR Reads the MHC-Peptide Complex

Every T cell displays thousands of copies of a single receptor type on its surface, the T cell receptor (TCR), generated through a randomized gene-shuffling process that produces an enormous diversity of possible shapes across the whole T cell population. When a TCR binds tightly enough to a specific MHC-peptide combination, it delivers what immunologists call signal 1. This is a recognition event, not yet a green light for action. The TCR is essentially checking two things at once: is this the right MHC scaffold, and is this a peptide it has been shaped to recognize as foreign. If the fit is close enough and sustained long enough, intracellular signaling cascades begin inside the T cell, clustering surface molecules and activating early transcription factors. But evolution built a safeguard into this system: recognition alone is not enough to commit a T cell to full activation. Peptides derived from the body's own proteins are also constantly displayed on MHC molecules, and TCRs that weakly recognize self-peptides slip through selection in the thymus. Signal 1 by itself is deliberately insufficient, which sets up the need for a confirming second signal before the cell acts.

Signal 2: Costimulation and the Two-Signal Model

The safeguard against autoimmunity is costimulation, commonly delivered when the CD28 receptor on the T cell binds B7 molecules (CD80/CD86) on the antigen-presenting cell. Crucially, APCs only upregulate B7 when they themselves have detected danger signals, such as bacterial products or tissue damage, through their own pattern-recognition receptors. This means B7 expression acts as a proxy for genuine threat context. A T cell that receives signal 1 (TCR-MHC recognition) without signal 2 (CD28-B7 costimulation) does not activate. Instead it becomes anergic, a state of functional tolerance in which the cell survives but becomes unresponsive to future stimulation, effectively neutralized. This is the two-signal model, and it is one of the immune system's central strategies for preventing autoimmunity: recognizing a self-peptide on an otherwise quiet, non-inflamed cell yields anergy rather than attack, because no dangerous inflammatory context was present to trigger B7. Only when both signals coincide, specific recognition plus confirmed danger, does the T cell proceed to full activation, secreting the growth factor interleukin-2 and preparing to divide.

Clonal Expansion: From One Cell to Thousands

Once both signals are satisfied, the activated T cell undergoes clonal expansion, a burst of rapid cell division that can produce thousands of genetically identical daughter cells over the course of several days. This solves a fundamental numbers problem: because each T cell's receptor is essentially unique, the initial population specific to any given pathogen is vanishingly small, perhaps only a handful of cells among billions circulating in the body. Interleukin-2 signaling drives these founder cells through repeated rounds of division, roughly doubling the responding population every few hours during the peak expansion phase. The result is an army of effector cells all carrying the identical TCR that first recognized the threat, dramatically increasing the odds of finding and clearing every infected cell or invading microbe. This expansion phase is also why an infection's symptoms often worsen for several days before improving. The adaptive immune response needs time to scale up, unlike the innate immune system's immediate but less targeted reaction. After the pathogen is cleared, most of these effector cells die off, while a smaller population persists as memory cells, ready to respond faster on any future encounter.

Differentiation: Helper Versus Cytotoxic T Cells

As activation and expansion proceed, T cells commit to one of two broad functional paths, largely determined by which co-receptor they carry alongside their TCR. CD4+ T cells, also called helper T cells, recognize peptides on MHC class II and specialize in coordinating the rest of the immune response rather than killing directly. They release cytokines that activate B cells to produce antibodies, recruit and energize macrophages, and support the expansion of cytotoxic T cells, acting as the response's command layer. CD8+ T cells, or cytotoxic T cells, recognize peptides on MHC class I, which is displayed by virtually every nucleated cell in the body, allowing them to survey tissues for signs of infection from the inside. Once activated, CD8+ effector cells directly kill infected or cancerous cells by releasing perforin and granzymes that trigger the target cell's controlled death, or by engaging death receptor pathways. This division of labor, helpers that coordinate versus killers that execute, means the two-signal activation process happening back in the lymph node ultimately produces two complementary forces working together throughout the body to contain and eliminate a threat.

Frequently asked questions

Try it live

Everything above runs in your browser — open T Cell Activation: How the Immune System Learns to Recognize a Threat and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.